Approach to Hypersensitivity and Autoimmune Conditions Flashcards
Type 1 Immediate Hypersensitivity
antigen exposure
IgE cross-linking on mast cell/basophil surfaces
histamine, leukotriene, prostaglandin, tryptase (mediators) release
symptoms of urticaria, rhinitis, wheezing, diarrhea, vomiting, hypotension, and anaphylaxis within minutes of exposure
*may have symptom return 4-8 hours after exposure
examples of type 1 hypersensitivity
pollen allergies, dust mite allergy, bee sting
Type 2 Cytotoxic Hypersensitivity
IgM or IgG antibody destroys cells by
- opsonization
- complement-mediated lysis
- antibody-dependent cellular cytotoxicity
examples of type 2 cytotoxic hypersensitivity
ABO mismatch, Grave’s disease, myasthenia gravis
treatment for type 1
antihistamines
treatment for type 2
acetylcholinesterase inhibitors, plasmapheresis
Type 3 Immunocomplex Hypersensitivity
antigen-antibody complex formation
complexes activate complement and neutrophil infiltration of tissue
tissue inflammation leading to fever, urticaria, generalized lymphadenopathy, arthritis, glomerulonephritis, vasculitis
examples of type 3
systemic lupus erythematosus, rheumatoid arthritis, farmer’s lung
treatment of type 3
supportive and avoidance of antigen
Type 4 Cell-Mediated Hypersensitivity
antigen exposure activates sensitized T-cells
T-cell activation leads to tissue inflammation 48-96 hours after exposure to antigen
examples of type 4
poison ivy rash, PPD testing for TB
type 4 treatment
symptomatic, steroids (rxn is result of T-cell activation, not histamine)
rheumatoid arthritis mechanism
systemic inflammatory disease affecting synovial membranes
granulation tissues develops in joint spaces and erodes into articular cartilage and bone
females moreso
genetic component
rheumatoid arthritis presentation
joint swelling, warmth, erythema, and decreased ROM
morning stiffness >1 hour
PIP, MCP, wrist, knees, and ankles are most commonly affected
rheumatoid arthritis treatment
disease-modifying anti-rheumatic drugs (DMARDs), NSAIDs, steroids, physical therapy
rheumatoid arthritis treatment risks
increased risk of infection from immunosuppression, 2x increase in incidence and mortality from leukemia or lymphoma, increased risk of CVD
juvenile idiopathic arthritis mechanism
collagen vascular disorder with persistent inflammation in 1 or more joints for 6 or more weeks in pt <16 y/o
onset at 1-3 y/o
females>males
juvenile idiopathic arthritis presentation
pauciarticular - large joints, asymmetric, iridocyclitis, uveitis
polyarticular - large and small joints, symmetric
systemic (Still’s disease) - recurrent high fevers, myalgias, pericarditis, lymphadenopathy, anemia, leukocytosis